vs
CBIZ, Inc.（CBZ）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是CBIZ, Inc.的1.9倍（$1.0B vs $542.7M），豪洛捷净利率更高（17.1% vs -14.6%，领先31.7%），CBIZ, Inc.同比增速更快（100.0% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $175.5M），过去两年CBIZ, Inc.的营收复合增速更高（13.7% vs 1.5%）
CBIZ, Inc.是美国知名的金融、保险及咨询服务提供商，总部位于俄亥俄州独立市，为美国规模最大的会计、保险经纪、金融与咨询服务机构之一。集团在全美设有120多个办事处，拥有近7000名员工，1996年起在纽交所上市，1997年起使用股票代码CBZ交易。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
CBZ vs HOLX — 直观对比
营收规模更大
HOLX
是对方的1.9倍
$542.7M
营收增速更快
CBZ
高出97.5%
2.5%
净利率更高
HOLX
高出31.7%
-14.6%
自由现金流更多
HOLX
多$39.7M
$175.5M
两年增速更快
CBZ
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $542.7M | $1.0B |
| 净利润 | $-79.4M | $179.1M |
| 毛利率 | — | 56.0% |
| 营业利润率 | 43.1% | 22.6% |
| 净利率 | -14.6% | 17.1% |
| 营收同比 | 100.0% | 2.5% |
| 净利润同比 | 4.2% | -10.9% |
| 每股收益（稀释后） | $-1.28 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBZHOLX
| Q1 26 | $542.7M | — | ||
| Q4 25 | $542.7M | $1.0B | ||
| Q3 25 | $693.8M | $1.0B | ||
| Q2 25 | $683.5M | $1.0B | ||
| Q1 25 | $838.0M | $1.0B | ||
| Q4 24 | $460.3M | $1.0B | ||
| Q3 24 | $438.9M | $988.0M | ||
| Q2 24 | $420.0M | $1.0B |
净利润CBZHOLX
| Q1 26 | $-79.4M | — | ||
| Q4 25 | $-79.4M | $179.1M | ||
| Q3 25 | $30.1M | $187.2M | ||
| Q2 25 | $41.9M | $194.9M | ||
| Q1 25 | $122.8M | $-17.4M | ||
| Q4 24 | $-90.7M | $201.0M | ||
| Q3 24 | $35.1M | $178.6M | ||
| Q2 24 | $19.8M | $194.5M |
毛利率CBZHOLX
| Q1 26 | — | — | ||
| Q4 25 | -9.4% | 56.0% | ||
| Q3 25 | 13.0% | 55.6% | ||
| Q2 25 | 12.9% | 56.3% | ||
| Q1 25 | 27.2% | 37.5% | ||
| Q4 24 | -13.4% | 56.8% | ||
| Q3 24 | 16.6% | 56.4% | ||
| Q2 24 | 12.8% | 55.4% |
营业利润率CBZHOLX
| Q1 26 | 43.1% | — | ||
| Q4 25 | -15.7% | 22.6% | ||
| Q3 25 | 8.5% | 22.6% | ||
| Q2 25 | 8.8% | 24.9% | ||
| Q1 25 | 23.9% | -0.7% | ||
| Q4 24 | -23.2% | 22.5% | ||
| Q3 24 | 11.3% | 23.3% | ||
| Q2 24 | 7.5% | 24.1% |
净利率CBZHOLX
| Q1 26 | -14.6% | — | ||
| Q4 25 | -14.6% | 17.1% | ||
| Q3 25 | 4.3% | 17.8% | ||
| Q2 25 | 6.1% | 19.0% | ||
| Q1 25 | 14.7% | -1.7% | ||
| Q4 24 | -19.7% | 19.7% | ||
| Q3 24 | 8.0% | 18.1% | ||
| Q2 24 | 4.7% | 19.2% |
每股收益（稀释后）CBZHOLX
| Q1 26 | $-1.28 | — | ||
| Q4 25 | $-1.22 | $0.79 | ||
| Q3 25 | $0.48 | $0.84 | ||
| Q2 25 | $0.66 | $0.86 | ||
| Q1 25 | $1.91 | $-0.08 | ||
| Q4 24 | $-1.84 | $0.87 | ||
| Q3 24 | $0.70 | $0.75 | ||
| Q2 24 | $0.39 | $0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.3M | $2.4B |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $1.8B | $5.2B |
| 总资产 | $4.4B | $9.2B |
| 负债/权益比越低杠杆越低 | — | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资CBZHOLX
| Q1 26 | $18.3M | — | ||
| Q4 25 | $18.3M | $2.4B | ||
| Q3 25 | $17.0M | $2.2B | ||
| Q2 25 | $39.8M | $1.9B | ||
| Q1 25 | $8.8M | $1.6B | ||
| Q4 24 | $13.8M | $2.0B | ||
| Q3 24 | $1.1M | $2.3B | ||
| Q2 24 | $1.1M | $2.4B |
总债务CBZHOLX
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
股东权益CBZHOLX
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $5.2B | ||
| Q3 25 | $1.9B | $5.0B | ||
| Q2 25 | $1.9B | $4.8B | ||
| Q1 25 | $1.9B | $4.6B | ||
| Q4 24 | $1.8B | $4.8B | ||
| Q3 24 | $927.9M | $5.1B | ||
| Q2 24 | $891.4M | $5.0B |
总资产CBZHOLX
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.4B | $9.2B | ||
| Q3 25 | $4.5B | $9.0B | ||
| Q2 25 | $4.5B | $8.8B | ||
| Q1 25 | $4.6B | $8.5B | ||
| Q4 24 | $4.5B | $8.7B | ||
| Q3 24 | $2.1B | $9.2B | ||
| Q2 24 | $2.2B | $8.9B |
负债/权益比CBZHOLX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.5M | $229.9M |
| 自由现金流经营现金流 - 资本支出 | $175.5M | $215.2M |
| 自由现金流率自由现金流/营收 | 32.3% | 20.5% |
| 资本支出强度资本支出/营收 | — | 1.4% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $444.5M | $1.0B |
8季度趋势，按日历期对齐
经营现金流CBZHOLX
| Q1 26 | $192.5M | — | ||
| Q4 25 | $143.6M | $229.9M | ||
| Q3 25 | $24.0M | $355.1M | ||
| Q2 25 | $113.1M | $343.3M | ||
| Q1 25 | $-88.3M | $169.4M | ||
| Q4 24 | $55.5M | $189.3M | ||
| Q3 24 | $43.7M | $367.0M | ||
| Q2 24 | $88.2M | $405.8M |
自由现金流CBZHOLX
| Q1 26 | $175.5M | — | ||
| Q4 25 | $141.7M | $215.2M | ||
| Q3 25 | $22.1M | $341.4M | ||
| Q2 25 | $105.2M | $330.5M | ||
| Q1 25 | $-93.4M | $153.9M | ||
| Q4 24 | $52.3M | $172.5M | ||
| Q3 24 | $41.1M | $350.6M | ||
| Q2 24 | $86.3M | $385.3M |
自由现金流率CBZHOLX
| Q1 26 | 32.3% | — | ||
| Q4 25 | 26.1% | 20.5% | ||
| Q3 25 | 3.2% | 32.5% | ||
| Q2 25 | 15.4% | 32.3% | ||
| Q1 25 | -11.2% | 15.3% | ||
| Q4 24 | 11.4% | 16.9% | ||
| Q3 24 | 9.4% | 35.5% | ||
| Q2 24 | 20.5% | 38.1% |
资本支出强度CBZHOLX
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 1.4% | ||
| Q3 25 | 0.3% | 1.3% | ||
| Q2 25 | 1.2% | 1.3% | ||
| Q1 25 | 0.6% | 1.5% | ||
| Q4 24 | 0.7% | 1.6% | ||
| Q3 24 | 0.6% | 1.7% | ||
| Q2 24 | 0.4% | 2.0% |
现金转化率CBZHOLX
| Q1 26 | — | — | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 0.79× | 1.90× | ||
| Q2 25 | 2.70× | 1.76× | ||
| Q1 25 | -0.72× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | 1.25× | 2.05× | ||
| Q2 24 | 4.45× | 2.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBZ
暂无分部数据
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
